These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 27143873)

  • 1. Prevention of COPD exacerbation by lysozyme: a double-blind, randomized, placebo-controlled study.
    Fukuchi Y; Tatsumi K; Inoue H; Sakata Y; Shibata K; Miyagishi H; Marukawa Y; Ichinose M
    Int J Chron Obstruct Pulmon Dis; 2016; 11():831-8. PubMed ID: 27143873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of ADRB2 polymorphisms on the efficacy of salmeterol and tiotropium in preventing COPD exacerbations: a prespecified substudy of the POET-COPD trial.
    Rabe KF; Fabbri LM; Israel E; Kögler H; Riemann K; Schmidt H; Glaab T; Vogelmeier CF
    Lancet Respir Med; 2014 Jan; 2(1):44-53. PubMed ID: 24461901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological effects of lysozyme on COPD and bronchial asthma with sputum: A randomized, placebo-controlled, small cohort, cross-over study.
    Ohbayashi H; Setoguchi Y; Fukuchi Y; Shibata K; Sakata Y; Arai T
    Pulm Pharmacol Ther; 2016 Apr; 37():73-80. PubMed ID: 26952317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial.
    Zheng JP; Wen FQ; Bai CX; Wan HY; Kang J; Chen P; Yao WZ; Ma LJ; Li X; Raiteri L; Sardina M; Gao Y; Wang BS; Zhong NS;
    Lancet Respir Med; 2014 Mar; 2(3):187-94. PubMed ID: 24621680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
    Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
    Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study.
    Zheng JP; Kang J; Huang SG; Chen P; Yao WZ; Yang L; Bai CX; Wang CZ; Wang C; Chen BY; Shi Y; Liu CT; Chen P; Li Q; Wang ZS; Huang YJ; Luo ZY; Chen FP; Yuan JZ; Yuan BT; Qian HP; Zhi RC; Zhong NS
    Lancet; 2008 Jun; 371(9629):2013-8. PubMed ID: 18555912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial.
    Decramer M; Celli B; Kesten S; Lystig T; Mehra S; Tashkin DP;
    Lancet; 2009 Oct; 374(9696):1171-8. PubMed ID: 19716598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose N-acetylcysteine in the prevention of COPD exacerbations: rationale and design of the PANTHEON Study.
    Zheng JP; Wen FQ; Bai CX; Wan HY; Kang J; Chen P; Yao WZ; Ma LJ; Xia QK; Gao Y; Zhong NS;
    COPD; 2013 Apr; 10(2):164-71. PubMed ID: 23061828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heart rate-lowering efficacy and respiratory safety of ivabradine in patients with obstructive airway disease: a randomized, double-blind, placebo-controlled, crossover study.
    Majewski S; Slomka S; Zielinska-Wyderkiewicz E; Ciebiada M; Gorski P
    Am J Cardiovasc Drugs; 2012 Jun; 12(3):179-88. PubMed ID: 22409211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial.
    Uzun S; Djamin RS; Kluytmans JA; Mulder PG; van't Veer NE; Ermens AA; Pelle AJ; Hoogsteden HC; Aerts JG; van der Eerden MM
    Lancet Respir Med; 2014 May; 2(5):361-8. PubMed ID: 24746000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of YuPingFeng granules on acute exacerbations of COPD: a randomized, placebo-controlled study.
    Ma J; Zheng J; Zhong N; Bai C; Wang H; Du J; Li F; Chen Y; Shi Z; Li X; Chen P
    Int J Chron Obstruct Pulmon Dis; 2018; 13():3107-3114. PubMed ID: 30323581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positive benefits of theophylline in a randomized, double-blind, parallel-group, placebo-controlled study of low-dose, slow-release theophylline in the treatment of COPD for 1 year.
    Zhou Y; Wang X; Zeng X; Qiu R; Xie J; Liu S; Zheng J; Zhong N; Ran P
    Respirology; 2006 Sep; 11(5):603-10. PubMed ID: 16916334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CXCR2 Antagonist MK-7123. A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease.
    Rennard SI; Dale DC; Donohue JF; Kanniess F; Magnussen H; Sutherland ER; Watz H; Lu S; Stryszak P; Rosenberg E; Staudinger H
    Am J Respir Crit Care Med; 2015 May; 191(9):1001-11. PubMed ID: 25695403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.
    Dransfield MT; Bourbeau J; Jones PW; Hanania NA; Mahler DA; Vestbo J; Wachtel A; Martinez FJ; Barnhart F; Sanford L; Lettis S; Crim C; Calverley PM
    Lancet Respir Med; 2013 May; 1(3):210-23. PubMed ID: 24429127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomised, double-blind, placebo-controlled trial of EPs 7630 in adults with COPD.
    Matthys H; Pliskevich DA; Bondarchuk OM; Malek FA; Tribanek M; Kieser M
    Respir Med; 2013 May; 107(5):691-701. PubMed ID: 23478193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exacerbations of chronic obstructive pulmonary disease.
    Wedzicha JA; Donaldson GC
    Respir Care; 2003 Dec; 48(12):1204-13; discussion 1213-5. PubMed ID: 14651761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monotherapy with indacaterol once daily reduces the rate of exacerbations in patients with moderate-to-severe COPD: Post-hoc pooled analysis of 6 months data from three large phase III trials.
    Wedzicha JA; Buhl R; Lawrence D; Young D
    Respir Med; 2015 Jan; 109(1):105-11. PubMed ID: 25433954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4.
    Rennard SI; Schachter N; Strek M; Rickard K; Amit O
    Chest; 2006 Jan; 129(1):56-66. PubMed ID: 16424413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiac safety profile of nebulized formoterol in adults with COPD: a 12-week, multicenter, randomized, double- blind, double-dummy, placebo- and active-controlled trial.
    Nelson HS; Gross NJ; Levine B; Kerwin EM; Rinehart M; Denis-Mize K;
    Clin Ther; 2007 Oct; 29(10):2167-78. PubMed ID: 18042473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Theophylline in the treatment of chronic obstructive pulmonary disease: a randomized, double-blind, placebo-controlled study].
    Zhou YM; Wang XP; Zeng XY; Qiu R; Xie JF; Liu SM; Zheng JP; Zhong NS; Ran PX
    Zhonghua Jie He He Hu Xi Za Zhi; 2006 Sep; 29(9):577-82. PubMed ID: 17129461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.